Latest Health News

Boab Metals has received the crucial regulatory green light for its Sorby Hills project, clearing the way for full-scale mining operations and first concentrate production targeted in late 2027.

KMD Brands has requested a voluntary suspension of its shares on both the NZX and ASX as it finalises a capital raise, refinancing, and its half-year financial results. The suspension aims to maintain market order while key details remain under negotiation.

Lumos Diagnostics has secured a pivotal US FDA CLIA waiver for its FebriDx® test, vastly expanding its market reach and triggering milestone payments that bolster its US commercial rollout.

RLF AgTech has raised $4.5 million through an institutional placement to accelerate its commercial rollout and meet rising demand amid global fertiliser shortages.

Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, paving the way for entry into Southeast Asia’s largest market. This milestone marks a significant step in the company’s international expansion strategy.

Australia and New Zealand Banking Group Limited (ANZ) has announced a quarterly distribution of AUD 1.4438 per security on its capital notes, payable in June 2026, with a 70% franking component and tax considerations for investors.

Gowing Bros Limited has announced a fully franked ordinary dividend of AUD 0.03 per share for the half-year ending January 2026, alongside a Dividend Reinvestment Plan offering shareholders a choice to reinvest without discount.

Thrive Tribe Technologies has completed a $240,554 capital raise through a discounted share placement, aiming to bolster its working capital. The placement involved issuing over 318 million shares at a 25% discount, with Clee Capital acting as lead manager.

OMG Group has reported a robust 53% increase in net sales for the first two months of FY26, driven by strong growth across retail and ecommerce channels. The company plans a strategic refresh of its Blue Dinosaur product range to maintain momentum.

PainChek has reported a strong quarter in the UK aged care sector, securing 4,000 new licenses and driving 9% quarter-on-quarter growth, signalling rising demand for its AI-driven pain assessment technology.

Nexsen Limited is advancing its rapid Group B Streptococcus test, StrepSure®, with a clear FDA submission timeline and early market entries across Asia-Pacific and emerging regions.

Eve Health Group is advancing its proprietary reformulation platform with two fast-onset products launched under Australia's SAS-B pathway, targeting large underserved markets in women's and men's health. The company’s capital-light, partner-led model aims for rapid revenue growth post-ARTG registration.